What does this research mean for the field?

Applying risk-based selection criteria for germline genetic testing in metastatic prostate cancer reduces costs threefold but results in missing 41% of clinically relevant pathogenic variants compared to universal testing. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To compare expected healthcare costs and the yield of pathogenic germline variants between universal testing and risk-stratified testing strategies in metastatic prostate cancer.

August 30, 2026Human GeneticsOpen Access

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer

View Full Paper

Ask AI

Bookmark

Authors

MVMichiel Vlaming LKLambertus A. Kiemeney WKWouter Koole

Discussion

Member takes

Overview

Modeling study reveals selective germline testing cuts costs threefold in metastatic prostate cancer, indicating risk-based screening misses 41% of actionable mutations.

Key Points

To compare expected healthcare costs and the yield of pathogenic germline variants between universal testing and risk-stratified testing strategies in metastatic prostate cancer.
Modeled a mainstream genetic testing pathway facilitated by non-genetic healthcare providers using Dutch national cancer incidence data, established cost frameworks, and estimated patient uptake rates.
Compared outcomes between offering genetic testing to all patients with metastatic prostate cancer versus restricting testing to patients with additional clinical risk factors.
Applying selection criteria reduced the overall costs of genetic testing and post-test counseling threefold compared to universal patient eligibility.
Restricting testing to patients with risk criteria missed 41% of clinically relevant pathogenic germline variants that universal testing identified.

Cite This Study

Vlaming et al. (2026) studied this question.

synapsesocial.com/papers/6a93f1266c1a8fb52e79dd77 https://doi.org/10.1007/s00439-026-02854-1

View Full Paper

Ask AI

Bookmark

August 30, 2026Human GeneticsOpen Access

Expected costs and benefits of genetic counselling and germline genetic testing in metastatic prostate cancer

View Full Paper

Ask AI

Bookmark

Authors

MVMichiel Vlaming LKLambertus A. Kiemeney WKWouter Koole

Discussion

Member takes

Overview

Modeling study reveals selective germline testing cuts costs threefold in metastatic prostate cancer, indicating risk-based screening misses 41% of actionable mutations.

Key Points

To compare expected healthcare costs and the yield of pathogenic germline variants between universal testing and risk-stratified testing strategies in metastatic prostate cancer.
Modeled a mainstream genetic testing pathway facilitated by non-genetic healthcare providers using Dutch national cancer incidence data, established cost frameworks, and estimated patient uptake rates.
Compared outcomes between offering genetic testing to all patients with metastatic prostate cancer versus restricting testing to patients with additional clinical risk factors.
Applying selection criteria reduced the overall costs of genetic testing and post-test counseling threefold compared to universal patient eligibility.
Restricting testing to patients with risk criteria missed 41% of clinically relevant pathogenic germline variants that universal testing identified.

Cite This Study

Vlaming et al. (2026) studied this question.

synapsesocial.com/papers/6a93f1266c1a8fb52e79dd77 https://doi.org/10.1007/s00439-026-02854-1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark